Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients (Q39325002)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Bart L. Haagmans

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Richard A. Lempicki

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Michael A. Polis

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

object named as

Amy Nelson

3

0 references

15

object named as

Shyam Kottilil

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Anu Osinusi

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Dimitra Bon

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yu-Jin Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Seerat Poonia

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Bhavana Shivakumar

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Shu Yi Cai

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Brad Wood

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Eva Herrmann

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Michael Sneller

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Henry Masur

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

26 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

86

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

177-185

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Immune activation and inflammation in HIV-1 infection: causes and consequences

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Phenotype and function of human T lymphocyte subsets: consensus and issues

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell Counts

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Hematologic disorders associated with hepatitis C virus infection and their management

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Evolving epidemiology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

HIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders Do

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Antiviral actions of interferons

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Elevated Serum Levels of Soluble Immune Activation Markers Are Associated with Increased Risk for Death in HAART-Naive HIV-1–Infected Patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Care of patients with hepatitis C and HIV co-infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Viral hepatitis and HIV co-infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Modeling HCV kinetics under therapy using PK and PD information

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23773

21 January 2018

Identifiers

10.1002/JMV.23773

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39325002&oldid=2144168866"